Employees: 485
Size Pacific Biosciences of California (PACB) is a United States Health Care company (Medical Specialties) with a market value of $573M, the 2575th largest of 3,085 United States companies the cockpit tracks. Shares closed at $1.83 on 18 Nov 2026.
Performance Over six months the shares gained 53.8%, against -2.1% for the median peer and -2.2% for the United States market (cap-weighted) — 4th highest of 19 in its peer set.
Growth Revenue grew 4.4% over the last twelve months (peer median +14.4%); the operating margin is -98.1% (peer median 7.4%).
Valuation It trades at 6.7× enterprise value to sales against a peer median of 5.5× (7th most expensive of 20).
Capital Return on invested capital runs 38.4 points below its cost of capital (10.3% WACC).
Backlog Backlog (remaining performance obligations) was $43.8M at 30 Sep 2026, down 10% on a year earlier — 0.3 years of trailing revenue. Backlog detail →
Short interest Short interest is 17.1% of the free float (30 Oct 2026).
Next results Next results expected around 18 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $161M | $160M | $154M | $201M | $128M |
| Revenue growth | — | +4% | -23% | +56% | — |
| Gross profit | $52.5M | -$319M | $23.7M | $40.3M | $48.9M |
| EBITDA | -$141M | -$165M | -$212M | -$278M | -$288M |
| Net income | -$131M | -$546M | -$310M | -$307M | -$314M |
| Free cash flow | -$143M | -$114M | -$212M | -$275M | -$280M |
| Capital expenditure | $13.5M | $7.71M | $6.19M | $8.84M | $16.9M |
| Total debt | $705M | $702M | $675M | $934M | $949M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | PACB | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -6.6% | -0.8% | 7th lowest of 19 |
| 6-month return | +53.8% | -2.1% | 4th highest of 19 |
| Distance from 52-week high | -46.7% | -31.6% | 6th lowest of 20 |
| Revenue growth (TTM) | +4.4% | +14.4% | 8th lowest of 20 |
| Operating margin | -98.1% | 7.4% | 2nd lowest of 20 |
| EV / Sales | 6.7× | 5.5× | 7th most expensive of 20 |
| ROIC minus cost of capital | -38.4 pp | -1.3 pp | 3rd lowest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Pacific Biosciences of California PACB | United States | $573M | +54% | +4% | -98% | 6.7× | n/a | n/a |
| Jiangsu Hanvo Safety Product 300952.SZ | China | $575M | -38% | +6% | 8% | 3.3× | n/a | n/a |
| Wuhan Huakang Century Clean Technology 301235.SZ | China | $563M | -57% | +28% | 7% | 1.6× | n/a | n/a |
| Cowealth Medical China 603122.SS | China | $562M | -34% | -18% | -5% | 5.9× | n/a | n/a |
| Orchestra BioMed OBIO | United States | $587M | +87% | +1,007% | -195% | 18.3× | n/a | n/a |
| Ningbo David Medical Device 300314.SZ | China | $589M | +25% | +19% | 11% | 5.4× | n/a | n/a |
| Hangzhou AGS MedTech 688581.SS | China | $590M | -22% | -18% | 33% | 3.7× | 0.4% | +27.8% |
| Tactile Systems Technology TCMD | United States | $592M | +6% | +14% | 9% | 1.5× | 8.4% | +12.0% |
| vVARDIS VVVV | United States | $594M | n/a | +148% | -72% | 14.3× | n/a | n/a |
| Sahajanand Medical Technologies SMT.NS | India | $595M | n/a | n/a | n/a | n/a | n/a | n/a |
| Sight Sciences SGHT | United States | $599M | +122% | +16% | -30% | 6.4× | n/a | n/a |
| Medistim MEDI.OL | Norway | $599M | +32% | +19% | 29% | 7.1× | -1.2% | +14.5% |
| Nanosonics NAN.AX | Australia | $599M | -4% | +3% | 7% | 3.8× | 35.3% | +6.7% |
| Contec Medical Systems 300869.SZ | China | $547M | -26% | -2% | -16% | 5.5× | 15.0% | -19.8% |
| Zhejiang Gongdong Medical Technology 605369.SS | China | $542M | -21% | +6% | 9% | 2.6× | 10.2% | +6.5% |
| Xvivo Perfusion XVIVO.ST | Sweden | $611M | -32% | +18% | 12% | 6.3× | 35.9% | +35.2% |
| Jin Medical International ZJYL | United States | $532M | +47% | -14% | 2% | 26.5× | n/a | n/a |
| Beijing Chunlizhengda Medical Instruments 688236.SS | China | $618M | -27% | -13% | 31% | 2.1× | -8.5% | +2.2% |
| Myriad Genetics MYGN | United States | $530M | +45% | -3% | -13% | 0.8× | n/a | n/a |
| AVITA Medical RCEL | United States | $529M | +290% | +17% | -34% | 6.7× | n/a | n/a |
| SunMax Biotechnology 4728.TWO | Taiwan | $630M | 0% | +19% | 51% | 8.3× | -2.6% | +18.8% |
Pacific Biosciences of California reported $43.8M of remaining performance obligations at 30 Sep 2026, down 10% from a year earlier and down 9% from the previous quarter. That is 0.3 years of trailing revenue already under contract. Book-to-bill last quarter: 0.90.